ConCallIQ
Go Pro
EMCUREPHARMACEUTICALS Healthcare 15 May 2026

Emcure Pharmaceuticals Ltd — Q4 FY26

Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and o...

bullish high
Compare with...
Revenue ₹2,470 Cr +16.7%
EBITDA ₹485 Cr +24.5%
PAT ₹244 Cr
EBITDA Margin 19.7% +130bps
Duration 65 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Geopolitical disruption impact on raw materials and freight

Rising solvent prices, insurance, and freight costs due to Middle East conflict could pressure margins if not passed through.

medium · analyst_question
R

Zuventus restructuring may take longer to stabilize

Despite management's confidence, the acute nature of Zuventus portfolio means sales recovery may take longer than expected.

medium · analyst_question
R

Semaglutide generic competition and pricing pressure

Multiple generic entrants in the GLP-1 market could limit Pista's market share and revenue contribution.

high · management_commentary
R

Currency volatility impacting international revenue

International business faces currency headwinds; guidance assumes average USD/INR of 92, but actual rates may vary.

low · data_observation